UBS Securities LLC has recently announced that it has increased stake in AnPac Bio-Medical Science Co. Ltd. (NASDAQ:ANPC) by 127.05%. After grabbing 5095.0 shares, the institutional investor is now in possession of 2851.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.27% having worth around $23845.0. Moreover, Jane Street Capital LLC increased its share by 1961.0 to have a control over 2887.0 shares. And Two Sigma Securities LLC raised its holdings to 1327.0 shares by acquiring 1327.0 shares or 0.07% of the stake.
AnPac Bio-Medical Science Co. Ltd. (ANPC) concluded trading on 01/19/23 at a closing price of $10.17, with 0.18 million shares of worth about $1.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 72.90% during that period and on Thursday the price saw a gain of about 14.53%. Currently the company’s common shares owned by public are about 2.02M shares, out of which, 1.74M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the ANPC stock and their offered price forecasts bring an average price target of $160.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $160.00 and could fall to a lowest price of $160.00. However, touching the estimated high of $160.00 would mean a gain of 93.64% for the stock.
The company recently came selling 1.0 shares which brought its stake up to 0.18% of the company’s outstanding shares.
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) started trading at $9.49, above $0.61 from concluding price of the previous day. However, the stock later moved at a day high price of 11.99, or with a gain of 14.53%. Stock saw a price change of 64.03% in past 5 days and over the past one month there was a price change of 192.24%. Year-to-date (YTD), ANPC shares are showing a performance of 117.31% which decreased to -54.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.60 but also hit the highest price of $23.80 during that period. The average intraday trading volume for AnPac Bio-Medical Science Co. Ltd. shares is 39.32K. The stock is currently trading 94.96% above its 20-day simple moving average (SMA20), while that difference is up 133.62% for SMA50 and it goes to 96.63% higher than SMA200.
UBS Securities LLC acquired 5095.0 shares of AnPac Bio-Medical Science Co. Ltd. having value of about $23845.0. Data submitted at the U.S SEC by UBS Securities LLC revealed that the firm now holds 2851.0 shares in the company valued at close to $28994.67, or have control over 127.05% stake in the company. AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) currently have 2.02M outstanding shares and institutions hold larger chunk of about 1.90% of that. Holding of mutual funds in the company is about 0.18% while other institutional holders and individual stake holders have control over 0.94% and — of the stake respectively.
The stock has a current market capitalization of $20.53M. It has posted earnings per share of -$280.25 in the same period. It has Quick Ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANPC, volatility over the week remained 19.70% while standing at 15.27% over the month.
Analysts are in expectations that AnPac Bio-Medical Science Co. Ltd. (ANPC) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.67 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -21.30%.
Analysts at 1 brokerage firms have issued recommendations for the AnPac Bio-Medical Science Co. Ltd. (ANPC)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.